← All trials
NCT04940741
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 7, 2021
- Primary completion
- Jun 28, 2023
- Completion date
- Dec 28, 2023
- First posted
- Jun 28, 2021
- Last posted
- Sep 21, 2021
- Enrollment
- 808
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Vertanical GmbHLead sponsor
- Schmerzzentrum BonnOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.